CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 20 enrolled
Drug / intervention
Ensifentrine 3 mg twice dailydrug
Likely dose
Ensifentrine 3 mg twice dailyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06460493
NCT06460493Phase 3Completed
CompareCT.gov

A Study Assessing the Effect of Ensifentrine on CAT™ Scores Over 12 Weeks in Subjects With Moderate to Severe COPD

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA·interventional·Posted Jun 14, 2024·Updated Apr 18, 2025

In Brief

A Phase 3 clinical trial evaluating Ensifentrine 3 mg twice daily for COPD. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this open-label, single center trial is to assess the effect of twice daily nebulized ensifentrine (3 mg) on COPD symptoms measured by the COPD Assessment Test (CAT™) scores over 12 weeks in subjects with symptomatic, moderate to severe COPD, taking maintenance LAMA/LABA or LAMA/LABA/ICS therapy. Subjects will continue the maintenance treatment during study participation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesUnited States
CollaboratorsMidwest Chest Consultants

Timeline

Phase 3CompletedFinished
20252026
First PostedJun 14, 2024
Enrollment StartJun 11, 2024
Primary CompletionNov 26, 2024
Study CompletionDec 3, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.1 years ago

Interventions

Ensifentrine 3 mg twice dailydrug

All subjects will receive ensifentrine.